Patrick J. Langlois

Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA

The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands.

Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France.

Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA.

DrugAbuse Sciences SAS develops therapies for treatment of alcohol abuse and opiate addiction. It also operates an educational website which is designed to provide clinicians, patients access to information and services related to alcohol abuse treatment and care. The company is headquartered in Lyon, France

Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.

Laboratoires Cyclopharma SA manufactures pharmaceutical preparations. The company is headquartered in Saint-Beauzire, France.

PJL Consulting provides business and management consulting services.

Part of Inoviem Scientific SAS, ArkAb SAS develops, manufactures, and commercializes raw materials for research in immunology and in vitro diagnostic market. The company is based in Limoges, France. The French company was founded in 2018. The CEO is Gaël Champier.

B Cell Design SAS provides pharmaceutical services. It offers research and development services in producing antibodies. The firm serves as a platform for other diagnostic and pharmaceutical companies addressed to academic laboratories and industrial research. The company was founded in December 7, 2007 and is headquartered in Limoges, France.

Stallergenes Greer Ltd. is a healthcare company, which engages in the development and commercialization of allergy immunotherapy products and services. Its products include sublingual products, subcutaneous products, and veterinary products. The company was founded on December 6, 2013 and headquartered in London, the United Kingdom.